Literature DB >> 30158165

An exploratory natural history of ataxia of Charlevoix-Saguenay: A 2-year follow-up.

Cynthia Gagnon1, Isabelle Lessard2, Caroline Lavoie2, Isabelle Côté2, Raphaël St-Gelais2, Jean Mathieu2, Bernard Brais2.   

Abstract

OBJECTIVE: To document the decline of upper and lower limb functions, mobility, and independence in daily living activities in adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) over a 2-year period.
METHODS: An exploratory longitudinal design was used. Nineteen participants were assessed on 2 occasions 2 years apart. Assessments included the Standardized Finger Nose Test, Nine-Hole Peg Test, Lower Extremity Motor Coordination Test, Berg Balance Scale, 10-m walk test (10mWT), 6-minute walk test (6MWT), Scale for the Assessment and Rating of Ataxia (SARA), and Barthel Index.
RESULTS: A significant decline was observed between baseline and follow-up for lower limb coordination, balance, walking abilities (10mWT and 6MWT), and overall disease severity (SARA). All differences were beyond measurement error documented in ARSACS. Results showed no significant decline for upper limb coordination and fine dexterity performance.
CONCLUSION: Although ARSACS is a slow, progressive disease, results showed that mobility, balance, and lower limb performance significantly decreased over the 2-year period and that selected outcome measures were able to capture this decline beyond measurement errors.
© 2018 American Academy of Neurology.

Entities:  

Mesh:

Year:  2018        PMID: 30158165      PMCID: PMC6177270          DOI: 10.1212/WNL.0000000000006290

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

1.  ARSACS, a spastic ataxia common in northeastern Québec, is caused by mutations in a new gene encoding an 11.5-kb ORF.

Authors:  J C Engert; P Bérubé; J Mercier; C Doré; P Lepage; B Ge; J P Bouchard; J Mathieu; S B Melançon; M Schalling; E S Lander; K Morgan; T J Hudson; A Richter
Journal:  Nat Genet       Date:  2000-02       Impact factor: 38.330

2.  Standardized finger-nose test validity for coordination assessment in an ataxic disorder.

Authors:  Cynthia Gagnon; Jean Mathieu; Johanne Desrosiers
Journal:  Can J Neurol Sci       Date:  2004-11       Impact factor: 2.104

3.  Upper-extremity motor co-ordination of healthy elderly people.

Authors:  J Desrosiers; R Hébert; G Bravo; E Dutil
Journal:  Age Ageing       Date:  1995-03       Impact factor: 10.668

4.  Two-, six-, and 12-minute walking tests in respiratory disease.

Authors:  R J Butland; J Pang; E R Gross; A A Woodcock; D M Geddes
Journal:  Br Med J (Clin Res Ed)       Date:  1982-05-29

5.  Reference values for developing responsive functional outcome measures across the lifespan.

Authors:  Marnee J McKay; Jennifer N Baldwin; Paulo Ferreira; Milena Simic; Natalie Vanicek; Joshua Burns
Journal:  Neurology       Date:  2017-03-22       Impact factor: 9.910

6.  Assessing mobility and balance in Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay population: Validity and reliability of four outcome measures.

Authors:  Isabelle Lessard; Bernard Brais; Isabelle Côté; Caroline Lavoie; Matthis Synofzik; Jean Mathieu; Cynthia Gagnon
Journal:  J Neurol Sci       Date:  2018-03-30       Impact factor: 3.181

7.  Validity and reliability of the LEMOCOT in the adult ARSACS population: A measure of lower limb coordination.

Authors:  Isabelle Lessard; Caroline Lavoie; Isabelle Côté; Jean Mathieu; Bernard Brais; Cynthia Gagnon
Journal:  J Neurol Sci       Date:  2017-03-29       Impact factor: 3.181

8.  Validation of a new lower-extremity motor coordination test.

Authors:  Johanne Desrosiers; Annie Rochette; Hélène Corriveau
Journal:  Arch Phys Med Rehabil       Date:  2005-05       Impact factor: 3.966

9.  Autosomal recessive spastic ataxia of Charlevoix-Saguenay.

Authors:  J P Bouchard; A Barbeau; R Bouchard; R W Bouchard
Journal:  Can J Neurol Sci       Date:  1978-02       Impact factor: 2.104

10.  Reliability and validity of the scale for the assessment and rating of ataxia: a study in 64 ataxia patients.

Authors:  Anja Weyer; Michael Abele; Tanja Schmitz-Hübsch; Beate Schoch; Markus Frings; Dagmar Timmann; Thomas Klockgether
Journal:  Mov Disord       Date:  2007-08-15       Impact factor: 10.338

View more
  4 in total

1.  Reliability and validity of digital health metrics for assessing arm and hand impairments in an ataxic disorder.

Authors:  Cynthia Gagnon; Olivier Lambercy; Christoph M Kanzler; Isabelle Lessard; Roger Gassert; Bernard Brais
Journal:  Ann Clin Transl Neurol       Date:  2022-02-27       Impact factor: 4.511

Review 2.  Documenting manifestations and impacts of autosomal recessive spastic ataxia of Charlevoix-Saguenay to develop patient-reported outcome.

Authors:  Marjolaine Tremblay; Laura Girard-Côté; Bernard Brais; Cynthia Gagnon
Journal:  Orphanet J Rare Dis       Date:  2022-10-01       Impact factor: 4.303

3.  Docosahexaenoic acid in ARSACS: observations in two patients.

Authors:  Ivana Ricca; Alessandra Tessa; Rosanna Trovato; Giacomo Maria Bacci; Filippo Maria Santorelli
Journal:  BMC Neurol       Date:  2020-05-28       Impact factor: 2.474

4.  Clinico-Genetic, Imaging and Molecular Delineation of COQ8A-Ataxia: A Multicenter Study of 59 Patients.

Authors:  Andreas Traschütz; Tommaso Schirinzi; Lucia Laugwitz; Nathan H Murray; Craig A Bingman; Selina Reich; Jan Kern; Anna Heinzmann; Gessica Vasco; Enrico Bertini; Ginevra Zanni; Alexandra Durr; Stefania Magri; Franco Taroni; Alessandro Malandrini; Jonathan Baets; Peter de Jonghe; Willem de Ridder; Matthieu Bereau; Stephanie Demuth; Christos Ganos; A Nazli Basak; Hasmet Hanagasi; Semra Hiz Kurul; Benjamin Bender; Ludger Schöls; Ute Grasshoff; Thomas Klopstock; Rita Horvath; Bart van de Warrenburg; Lydie Burglen; Christelle Rougeot; Claire Ewenczyk; Michel Koenig; Filippo M Santorelli; Mathieu Anheim; Renato P Munhoz; Tobias Haack; Felix Distelmaier; David J Pagliarini; Hélène Puccio; Matthis Synofzik
Journal:  Ann Neurol       Date:  2020-06-10       Impact factor: 11.274

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.